Overview
Our Approach
Community Involvement
Overview
Sheila Mikhail
Jennifer Anderson
Timothy Ferguson
Fred Johnson
Overview
BioFuels
Clinical Trials
Due Diligence
Entrepreneurial Services
Intellectual Property Management
Joint Ventures and Strategic Alliances
Mergers and Acquisitions
Reduction of Costs
Technology Transfers & Licensing
Venture Capital Financing
Overview
LSL Articles and Presentations
Research Triangle Resources
Entrepreneurial Resources
Life Sciences & Technology Resources
Firm News
Client News
Contact Us
Driving Directions
Recruiting

Transactions

  • Major Licensing Transactions
    • Cross-License Agreement between Asklepios BioPharmaceutical, Inc. and Genzyme Corporation, a sanofi company.
    • Collaboration and License Agreement between Entegrion, Inc. and Kedrion Melville, Inc.
    • Software License Agreement between InnerOptic Technology, Inc. and Pathfinder Therapeutics, Inc.
    • Licensing Agreement between Chatham Therapeutics, LLC. and Baxter International, Inc.
    • IP Sublicense Agreement between Grilols S.A. and Kedrion S.p.A.
    • Cross-License Agreement between Asklepios BioPharmaceutical, Inc. and GlaxoSmithKline, Inc.
    • License Agreement between Immunovaccine, Inc. and Immunotopoe, Inc.
    • License Agreement between Immunovaccine, Inc. and Merck KGaA.
    • License Agreement between Asklepios BioPharmaceutical, Inc. and Pfizer, Inc.
    • License Agreement between Immunovaccine, Inc. and Pfizer, Inc.
    • Option Agreement and License Agreement between BioClassifier, LLC and NanoString Technologies, Inc.
    • Cross-License Agreement between GlaxoSmithKline and Asklepios BioPharmaceutical, Inc.
    • Collaboration and License Agreement between Novo Nordisk and BioStratum Inc.
    • License Agreement between DakoCytomation Denmark A/S and BioStratum Inc.
    • Cross-License Agreement between AGTC, Inc. and Asklepios BioPharmaceutical, Inc.
    • License Agreement between Athena Diagnostics, Inc., a subsidiary of Elan Pharmaceuticals Inc., and BioStratum Inc.
    • License Agreement between Senju Pharmaceuticals and AcSentient, Inc.
    • Trademark License Agreement between Bayer HealthCare LLC and Laboratories Gador S.A.
    • License Agreement between University of West Virginia Medical Center and AcSentient, Inc.
    • Collaboration Agreement between Dow Chemical Company and Nobex Corporation
    • Collaboration Agreement between Bayer HealthCare LLC and Asklepios BioPharmaceutical Inc.
    • Collaboration Agreement between Nobex Corporation and Biocon Ltd.
    • License Agreement between Bayer HealthCare LLC and Bausch & Lomb Inc.
    • License Option Agreement between Bayer HealthCare LLC and American National Red Cross
    • License Agreement between Bayer HealthCare LLC and Clearant Inc.
    • License Agreement between NanoCor Therapeutics Inc. and the University of Washington
    • License Agreement between Crucell Holland B.V. and Talecris Biotherapeutics, Inc.
    • License Agreement between Gilead Sciences, Inc. and Diatos S. A.
    • License Agreement between Nobex Corporation and Dow Chemical
    • License and Development Agreement between Talecris and Bausch & Lomb for development of recombinant products.
    • License Agreement between Baxter and a biotech for a rFix product
    • Collaboration and Development Agreement between Talecris Biotherapeutics, Inc. and Activaero GmbH

  • Mergers and Acquisitions
    • Sale of Common Shares by Scott D. Martin to MRMC.
    • Unit Purchase Agreement between American Detection Technologies, LLC and Titan Global, LLC.
    • Settlement and Sale of Shares to East Texas Mack, Inc.
    • Sale of Talecris Biotherapeutics, Inc. Equity in Centric Health Resources, Inc.
    • Sale of Assets by Physicians Waste Services, Inc. to Healthcare Waste Management, Inc.
    • Sale of Assets in American Detection Technologies, LLC to Titan Global, LLC.
    • Sale of Assets in Dorsan Biofuels, Inc. to Novozymes A/S.
    • Acquisition of Hemascan technology by Bayer Corporation from Arrowhead, LLC
    • Sale of assets by AcSentient, Inc. to ISTA Pharmaceuticals, Inc.
    • Sale of assets by Angiomics, Inc to Protein Design Labs, Inc.
    • Acquisition by Aventis S.A. of secured debt interest in Scynexis, Inc.
    • Sale of StarLink Logistics Inc. interest in Tech Pac LLC to Central Garden & Pet Company (Nasdaq:CENT)
    • Divestiture of Tech Pac, LLC by Aventis to Central Garden & Pet Company
    • Acquisition of stock of Raylo Chemicals, Inc. from Degussa SA by Gilead Sciences, Inc.
    • Acquisition of Hemascan technology by Bayer Corporation from Arrowhead, LLC
    • Sale of stock in TherapyEdge, Inc. to institutional investors
    • Sale by StarLink Logistics, Inc. and Aventis Pharmaceutical of various real estate assets
    • Acquisition of patented technology by NanoCor Therapeutics, Inc. from Johns Hopkins University

  • University Spin-Outs
    • Duke University spin out of technology to ZumaTek, Inc.
    • Massachusetts General, Harvard University - spin out of technology to NanoCor Therapeutics, Inc.
    • Washington University the University of Utah and the University of North Carolina, Chapel Hill spin out of technology to University Genomics Inc.
    • UNC-Chapel Hill - spin-out of technology to InnerOptic, Inc., a newly formed company
    • UNC-Chapel Hill - spin-out of technology to Asklepios BioPharmaceutical, Inc., a newly formed company
    • UNC-Chapel Hill - spin-out of technology to Karyogen, Inc., a newly formed company
    • UNC-Chapel Hill- spin-out of technology to Invitrox, Inc., a newly formed company
    • University of Eastern Virginia Medical School - spin-out of technology to AcSentient, Inc., a newly formed company)
    • NanoCor Therapeutics Inc. spin-out from Asklepios BioPharmaceutical, Inc.
    • UNC-Chapel Hill and University of Florida - license of technology to Molecular Orthopaedics, Inc.
    • UNC-Chapel Hill - license of technology to Institute for OneWorld Health
    • Duke University - license of technology to Angiomics, Inc.
    • Duke University - license of technology to Novelios Pharmaceuticals, Inc.
    • University of California - Berkeley - license of technology to Bayer HealthCare LLC
    • North Carolina State University - license of technology to Silkore, Inc.
    • Massachusetts General, Harvard University - license of technology to NanoCor Therapeutics, Inc.
    • Washington University, the University of Utah and the UNC - Chapel Hill license of technology to University Genomics Inc.

  • Collaboration and Development Agreement
    • Co-Promotion Agreement between Talecris Biotherapeutics, Inc. and Novartis Animal Health. Inc.
    • Research Agreement between ImmunoVaccine Technologies, Inc. and OncoTherapy Science, Inc.
    • Commercialization Agreement between Inspiration Biopharmaceuticals, Inc. and Ipsen Pharma S.A.S.
    • Collaboration and Development Agreement between Talecris Biotherapeutics, Inc and Activaero GmbH
    • Co-Development Agreement between Talecris Biotherapeutics, Inc and Bausch & Lomb Incorporated
    • BioProcessing Services Agreement between Talecris Biotherapeutics, Inc. and Diosynth RTP Inc.
    • Co-Development and License Agreement between Talecris Biotherapeutics, Inc. and Bausch & Lomb Inc.
    • Development Agreement between Bayer HealthCare LLC and Mallinckrodt Baker, Inc.
    • Development Agreement between Talecris Biotherapeutics, Inc. and British Biocell International (BBI)
    • Product Agreement between Gilead Sciences, Inc. and Diatos S.A.
    • Development and Manufacturing Agreement for blood and plasma screening reagents between Bayer Corporation and Roche
    • Agreement for the manufacture, supply, and distribution of drugs by Sumitomo in Japan on behalf of a Gilead Sciences, Inc.
    • Development Agreement for the development of monoclonal antibodies
    • Co-Development and Manufacture Agreement for a plasma derived anthrax product
    • Joint venture for the development and commercialization of a rFIX product
    • Product Supply Agreement between Emergent Product Development Gaithersburg Inc. and Talecris Biotherapeutics, Inc.

  • Manufacturing and Distribution Agreements
    • Commercial Supply Agreement between Inspiration Biopharmaceuticals, Inc. and CMC ICOS.
    • Manufacture and Distribution Agreement between Gilead Sciences, Inc. and Aspen Pharmacare Holdings Limited
    • Purchase and Sale Back Agreement between Talecris Biotherapeutics, Inc. and and Kedrion S.p.A.
    • Product Supply Agreement between and Talecris Biotherapeutics, Inc. and Emergent Product Development Gaithersburg Inc.
    • European Product Sales Agreement between Talecris Biotherapeutics, GmbH and Bayer Biologicals S.r.l.
    • Supply Agreement between Talecris Biotherapeutics, Inc and Bausch & Lomb Incorporated
    • Supply Agreement between Gilead Sciences, Inc. and Degussa AG

  • Strategic Alliance Transactions
    • Services Agreement between InnerOptic Technology, Inc. and Microsulis Medical Limited, Inc.
    • Manufacturing Agreement of drugs between Bayer and B. Braun Medical Inc.
    • Services Agreement between Bayer HealthCare LLC and Canadian Blood Services (CBS)
    • Services Agreement between Talecris Biotherapeutics, Inc. and Bayer technology Services (BTS)
    • Services Agreement between Talecris Biotherapeutics, Inc. and Bayer S.A. (SLA)
    • Distribution Arrangements in China for Bayer Corporation
    • Distribution Arrangements in Brazil for Bayer Corporation
    • Distribution Arrangements in South America for Bayer

  • Financing
    • Restructuring and Financing for Inspiration Biopharmaceuticals, Inc.
    • Series D Preferred Stock Financing by Aspen Avionics, Inc. to private investors.
    • Series C Preferred Stock Financing by Entegrion, Inc. to private investors.
    • Series B Preferred Stock Financing by Heat Biologics, Inc. to private investors.
    • Sale of convertible note to Ipsen Pharma S.A.S. ($25m) by Inspiration Biopharmaceuticals, Inc.
    • Sale of convertible note to Ipsen Pharma S.A.S. ($35m) by Inspiration Biopharmaceuticals, Inc.
    • Sale of Series B Preferred to Celtic Pharma Management, L.P. and other investors by Inspiration Biopharmaceuticals, Inc.
    • Sale of Series C Preferred Stock to Ipsen Pharma S.A.S. by Inspiration Biopharmaceuticals, Inc.
    • Series B Preferred Stock Financing by NanoCor Therapeutics, Inc. to Medtronic, Inc.
    • Secondary transfer of MRMC Common Shares to Institutional Investors.
    • Sale of convertible note to Ipsen Pharma S.A.S. ($50m) by Inspiration Biopharmaceuticals, Inc.
    • Series C Preferred Stock Financing by BioResource International, Inc. to private investors
    • Series A Preferred Stock Financing by Asklepios BioPharmaceutical, Inc. to private investor
    • Series A Preferred Stock Financing by NanoCor Therapeutics, Inc. to private investor
    • Series B Preferred Stock Financing by NanoCor Therapeutics Inc. to Medtronic, Inc.
    • Series A Preferred Stock Financing by Inspiration Biopharmaceuticals, Inc. to Celtic Management, LP
    • Sales of common stock in Inspiration Biopharmaceuticals, Inc. to private investors

  • Clincal Trials
©2013 Life Sciences Law